Research progress of biomarkers for predicting the efficacy of immunotherapy for tumor / 国际肿瘤学杂志

ABSTRACT

Immonocheckpoint inhabitors have become the focus of tumor therapy in recent years, and more and more tumor patients benefit from immunotherapy. Due to the high cost of immunotherapy, the benefit rate of immunotherapy for untested population is only 20%. Therefore, accurate selection of predictive biomarkers is crucial for individualized immunotherapy of tumor patients. Biomarkers reflecting tumor immune microenvironment and tumor cell intrinsic features, such as programmed death-1 (PD-1) and its ligand PD-L1, tumor mutational burden and microsatellite instability, have been proved to associate with treatment effect of anti-PD-1/anti-PD-L1 therapy. At the same time, markers based on tissue and serum emerge in endlessly. How to truly achieve accurate immunotherapy for tumor needs further clinical research.